On May 10, 2024, the United States Patent and Trademark Office (USPTO) issued a notice of proposed rulemaking that, if enacted, would tie the enforceability of every claim of a patent subject to a terminal disclaimer to the validity of any claim of the reference patent. In other words, if any claim of the reference
Latest Post
More Posts
USPTO Emphasizes Searches of FDA Databases for Pharmaceutical Patent Applications
Life Sciences Companies Make Up a Small Portion of the Companies Opting-In to the Unitary Patent; Ireland Announces Referendum Date
K-Fee Provides a Warning to Life Sciences Companies – What You Say in Foreign Prosecution May Affect Your U.S. Claim Scope
Tillis Bill to Amend Section 101 of the Patent Act
FDA’s Woodcock Reviews Patents Practices as a Way to Effect Drug Pricing
Alvotech Files Suit Against AbbVie to Invalidate Humira Patent Portfolio
Subscribe: Subscribe via RSS
Firm/Org